ON THE PEN

ON THE PEN

Novo Nordisk Just Changed the Childhood Obesity Conversation

New data helps to bolster the case for early pharmacologic obesity interventions.

On The Pen GLP-1 News's avatar
On The Pen GLP-1 News
Sep 07, 2026
∙ Paid

Novo Nordisk released the first top-line results from its STEP Young phase 3 trial this morning, and the headline number is going to be difficult to ignore. After 68 weeks, 40.4% of children ages 6 to under 12 treated with semaglutide were no longer classified as having obesity, compared with 0% of children receiving placebo.

I already know where a lot o…

Keep reading with a 7-day free trial

Subscribe to ON THE PEN to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2026 OTP Media Corp. · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for writing, podcasting, and media founders.